Discover our Portfolio
The company Diaccurate, founded in December 2012, aims at developing new treatments to fight HIV infection. Diaccurate has obtained a worldwide and exclusive patent license from the Pasteur Institute. The treatment under development in the field of HIV is based on a major innovation which targets a protein “RIF” responsible for the immunological disease (inactivated CD4 T lymphocytes) observed in AIDS. Clinical trials are expected to begin in 2018.